Approved for use through 12/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
as collection of information unless it disclayers until CMM control united to the control of the contro

TERMINAL DISCLAIMER TO OBVIATE A PROVISION		Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE		FN101-CIP-US
	_ ,	
In re Application of: Michael J. DeLuca, et al.		
Application No.: 10/635,862		
Filed: August 5, 2003		
For: DETECTING RED EYE FILTER AND APPARATUS USING META-DATA		
The owner*. <u>Footballot Valors United</u> of 100, persont interest in the instant application hereby disclarine, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which undertad byeard the expiration date of the full statutory term of any patent granted on pending reference Application. Number 10(855.918 field on August 5, 2003 so such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent or any patent granted on said reference application may be shortened spiral control of the grant of any patent or the prending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that that any patent by indirect part of the granter, its successors or assigns of the production and is binding upon the granter, its successors or assigns the successors or assigns the production and is binding upon the granter, its successors or assigns the successors or assigns the production and is binding upon the granter, its successors or assigns the successors are assigns to the successor and the successor and the successors are assigns to the successor and the successor are assigns to the successor and the successo		
In making the above disclaimer, the owner does not disclaim the terminal part of any patient granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patient granted on said reference application, "as the term of any patient granted on said reference application," as the term of any patient in the product of the grant of any patient of the pending reference application, in the event that any such patient granted or the pending reference application, expires for failure to pay a maintenance lee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all dains canceld by a reoxamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer floor for to its grant.		
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record. Reg. No.	43,132	
/Andrew Vernon	Smith/	December 27, 2007
Signature		Date
Andrew V. Smith		
Typed or printed name		
		415-203-2782
		Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).		
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.		
This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is powerped by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete.		

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including pathering-perapria, and submitting the completed application from the USPTO. Time well vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this hurden, should be sent to the Chief Information Office, U.S. Patent and Transact Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.